Michael Didriksen
Senior Director Lundbeck
Seminars
Thursday 17th September 2026
Panel Discussion: To What Degree Does Neuroplasticity Underpin Psychedelic Efficacy?
9:15 am
- Examining the evidence linking psychedelic induced synaptic and dendritic remodeling with changes in mood, cognition and emotional processing
- Exploring whether neuroplasticity is a mechanistic driver of efficacy or a downstream accompaniment to broader network level changes
- Comparing plasticity linked biomarkers, such as EEG signatures, sleep architecture shifts and neurotrophic factor changes, to determine which most reliably map onto clinical response
- Debating how much neuroplasticity is necessary, sufficient or even predictive for therapeutic benefit across different psychedelic and non psychedelic compounds
- Considering maladaptive behaviors underpinned by neuroplasticity in the brain
- How might we treat “neuroplastogens” differently: as a separate class
Thursday 17th September 2026
Panel Discussion: Redefining Therapeutic Potential in Muscarinics: Interrogating the M1/M4 Debate to Advance Next Generation Neuropsychiatric Treatments
3:30 pm
- How the recent FDA approval of an M1/M4 targeting muscarinic agonist–antagonist therapy has opened the door for next generation mechanisms, prompting the field to explore which muscarinic pathways hold the greatest future therapeutic potential
- How M1 and M4 receptor modulation may diverge in future clinical applications, with emerging evidence suggesting distinct roles in cognitive processing, behavioural regulation, and symptom domains underserved by dopamine based treatments
- How advancing Phase 1 muscarinic programs is helping define optimal translational strategies for the future, including biomarker guided dosing, refined safety monitoring, and strategic choices around patient versus healthy volunteer enrolment
- How next generation M4 selective PAMs and other muscarinic focused innovations may expand the therapeutic footprint across neuropsychiatric and neurodegenerative indications, positioning muscarinic pathways as a long term pillar of future CNS drug development
- Will PAMs recapitulate efficacy of orthosteric agonists, as seen with Cobenfy?
